Navigate Fool.com
Will AZN beat
the market?
Community Rating: 4 Stars: Favorite

62.52 0.07 (0.11%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

Company Photos
(Click to zoom)
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $62.65
Previous Close $62.45
Daily Range $61.80 - $62.78
52-Week Range $46.87 - $68.76
Market Cap $78.6B
P/E Ratio 30.69
Dividend (Yield) $3.80 (4.5%)
Ex-Dividend Date
Dividend Pay Date
Volume 1,584,374
Average Daily Volume 1,765,879
Current FY EPS $4.32

How do you think AZN
will perform against the market?

Top AZN Bull/Bear Pitches


There are no pitches that meet the Top Bull criteria. Explain

If this upsets you, start recommending pitches here!


There are no pitches that meet the Top Bear criteria. Explain

If this upsets you, start recommending pitches here!

News & Commentary

The Supreme Court Will Decide the Fate of a Blockbuster

Teva's day in court is coming.

Today’s Top Biotech Stories: Lexicon, Alimera, and Akebia

Lexicon, Alimera, and Akebia are the top stories to watch in the biotech sector this Monday morning.

The AACR Annual Meeting May Move These 2 Stocks

The American Association for Cancer Research meeting shines a bright light on gene testing like that performed by Myriad, and on promising late stage breast cancer treatments, including Pfizer's palbociclib.

Partner Signed! Is Amarin's Turnaround Beginning?

Amarin Corporation plc (ADR) signed Japan's Kowa Pharmaceuticals as a marketing partner for Vascepa.

1 Experimental Breast Cancer Drug You Need to Know

This experimental therapy more than tripled progression-free survival in the most common type of breast cancer. Could it be set to revolutionize patient care as we know it?

Microsoft Charges to Lead the Dow's Hundred-Point Surge

Pfizer gains after yet another strong announcement from the Big Pharma giant.

From Marijuana to Snake Venom: 9 Drugs Derived from Unlikely Sources

Cannabis plants, snake venom, and snail venom are just some of the interesting sources drug developers have used to create these nine drugs.

3 Reasons to Buy Novavax, Inc.

Novavax's recent decline could be a compelling buying opportunity.

Here's How Sanofi Hopes to Survive Post-Lantus

Sanofi (SNY) hopes its promising new diabetes drug U300 will protect its top line when Lantus loses patent protection in 2015.

Do you take statins? If not, you may have to

See More AZN News...





AstraZeneca plc (ADR) (AZN) Description

The Company discovers, develops, manufactures and markets prescription pharmaceuticals for important areas of healthcare: cancer, cardiovascular, gastrointestinal, infection, neuroscience, and respiratory and inflammation. Website: http://www.astrazeneca.com/

Featured Broker Partners

Learn more about our new Fool ticker page!

Take a Tour
no thanks